S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
BREAKING: The truth about war with China (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
BREAKING: The truth about war with China (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
BREAKING: The truth about war with China (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
BREAKING: The truth about war with China (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
NASDAQ:GLYC

GlycoMimetics (GLYC) Stock Forecast, Price & News

$1.90
-0.02 (-1.04%)
(As of 06/2/2023 ET)
Compare
Today's Range
$1.85
$1.96
50-Day Range
$1.21
$2.08
52-Week Range
$0.51
$4.16
Volume
185,941 shs
Average Volume
960,645 shs
Market Capitalization
$122.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

GlycoMimetics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
321.1% Upside
$8.00 Price Target
Short Interest
Healthy
2.05% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.00mentions of GlycoMimetics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$67,995 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.74) to ($0.76) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

385th out of 983 stocks

Pharmaceutical Preparations Industry

183rd out of 486 stocks


GLYC stock logo

About GlycoMimetics (NASDAQ:GLYC) Stock

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

GLYC Stock News Headlines

15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Q1 2023 GlycoMimetics Inc Earnings Call
GlycoMimetics (NASDAQ:GLYC) Lowered to "Sell" at StockNews.com
This Small Pharma Company Could Develop Into a Nice Trade
See More Headlines

GLYC Price History

GLYC Company Calendar

Last Earnings
3/29/2023
Today
6/03/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLYC
Employees
52
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+321.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-46,690,000.00
Pretax Margin
-56,526.67%

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
$0.97 per share

Miscellaneous

Free Float
59,106,000
Market Cap
$122.08 million
Optionable
Optionable
Beta
2.10

Key Executives

  • Harout Semerjian
    President, Chief Executive Officer & Director
  • Brian M. Hahn
    Chief Financial Officer & Senior Vice President
  • Deepak Tiwari
    Vice President-Technical Operations
  • Edwin P. Rock
    Chief Medical Officer & Senior Vice President
  • Bruce Johnson
    Chief Commercial Officer & Senior Vice President













GLYC Stock - Frequently Asked Questions

Should I buy or sell GlycoMimetics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GLYC shares.
View GLYC analyst ratings
or view top-rated stocks.

What is GlycoMimetics' stock price forecast for 2023?

1 Wall Street research analysts have issued 1 year target prices for GlycoMimetics' stock. Their GLYC share price forecasts range from $8.00 to $8.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 321.1% from the stock's current price.
View analysts price targets for GLYC
or view top-rated stocks among Wall Street analysts.

How have GLYC shares performed in 2023?

GlycoMimetics' stock was trading at $3.03 at the beginning of the year. Since then, GLYC shares have decreased by 37.3% and is now trading at $1.90.
View the best growth stocks for 2023 here
.

When is GlycoMimetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our GLYC earnings forecast
.

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) released its quarterly earnings results on Wednesday, March, 29th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.02.

What other stocks do shareholders of GlycoMimetics own?
What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

Who are GlycoMimetics' major shareholders?

GlycoMimetics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include AXA S.A. (2.50%), Acadian Asset Management LLC (2.18%), BlackRock Inc. (1.01%), Two Sigma Advisers LP (0.93%), Two Sigma Investments LP (0.58%) and Affinity Asset Advisors LLC (0.00%). Insiders that own company stock include Brian M Hahn, Bruce S Johnson, Bvf Partners L P/Il, Daniel M Junius, Edwin Rock, John L Magnani, Patricia S Andrews, Public Equities LP Invus and Scott D Sandell.
View institutional ownership trends
.

How do I buy shares of GlycoMimetics?

Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GlycoMimetics' stock price today?

One share of GLYC stock can currently be purchased for approximately $1.90.

How much money does GlycoMimetics make?

GlycoMimetics (NASDAQ:GLYC) has a market capitalization of $122.08 million and generates $80,000.00 in revenue each year. The biotechnology company earns $-46,690,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.

How can I contact GlycoMimetics?

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The official website for the company is www.glycomimetics.com. The biotechnology company can be reached via phone at (240) 243-1201, via email at sannes@annesassociates.com, or via fax at 301-738-2137.

This page (NASDAQ:GLYC) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -